title: Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
abstract: Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.
authors.affiliation: Department of Hematology, Odense University Hospital, Sønder Boulevard 29, Odense 5000, Denmark. Electronic address: karen.mylam@rsyd.dk.
authors.forename: Karen Juul
authors.initials: KJ
authors.lastname: Mylam
authors.affiliation: Department of Nuclear Medicine, Odense University Hospital, Sønder Boulevard 29, Odense 5000, Denmark.
authors.forename: Anne Lerberg
authors.initials: AL
authors.lastname: Nielsen
authors.affiliation: Department of Hematology, Roskilde Hospital, Køgevej 7-13, Roskilde 4000, Denmark.
authors.forename: Lars Møller
authors.initials: LM
authors.lastname: Pedersen
authors.affiliation: Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark.
authors.forename: Martin
authors.initials: M
authors.lastname: Hutchings
mesh_terms: D019788:Fluorodeoxyglucose F18; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: FDG-PET; Lymphoma; Response criteria; Response evaluation; Staging; Surveillance